This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
by Zacks Equity Research
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
medical medical-devices
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
medical medical-devices
3 Medical Instrument Stocks to Counter Industry Woes Using GenAI
by Moumi Mondal
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
artificial-intelligence medical medical-devices
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
by Zacks Equity Research
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
medical medical-devices
Mitek Systems (MITK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth
by Moumi Mondal
HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.
medical medical-devices
Should You Continue to Hold BRKR Stock in Your Portfolio?
by Zacks Equity Research
Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.
medical medical-devices
Reasons to Retain Baxter International Stock in Your Portfolio Now
by Zacks Equity Research
BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
medical medical-devices
Is ISRG's 20% Procedure Growth the New Normal or a Peak?
by Indrajit Bandyopadhyay
ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.
medical medical-devices
SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio
by Zacks Equity Research
Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.
medical medical-devices